3/17
09:58 am
cadl
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]
Low
Report
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]
3/17
08:29 am
cadl
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors [Yahoo! Finance]
Low
Report
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors [Yahoo! Finance]
3/17
08:05 am
cadl
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Medium
Report
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
3/13
04:22 pm
cadl
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
Medium
Report
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
3/13
02:48 pm
cadl
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
Low
Report
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
3/12
09:47 am
cadl
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
Low
Report
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
3/12
08:05 am
cadl
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Low
Report
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
3/11
07:18 am
cadl
Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".
3/9
08:25 am
cadl
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting [Yahoo! Finance]
Medium
Report
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting [Yahoo! Finance]
3/9
08:05 am
cadl
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Medium
Report
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
3/5
07:52 am
cadl
Targeted therapies to join chemo as oncology treatment backbone [Yahoo! Finance]
Low
Report
Targeted therapies to join chemo as oncology treatment backbone [Yahoo! Finance]
3/2
04:05 pm
cadl
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/24
08:33 am
cadl
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston [Yahoo! Finance]
Low
Report
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston [Yahoo! Finance]
2/24
08:05 am
cadl
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
Low
Report
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
2/19
09:40 pm
cadl
Candel Therapeutics Announces Pricing of Public Offering
Low
Report
Candel Therapeutics Announces Pricing of Public Offering
2/19
04:53 pm
cadl
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering [Yahoo! Finance]
Medium
Report
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering [Yahoo! Finance]
2/19
04:05 pm
cadl
Candel Therapeutics Announces Proposed $100 Million Public Offering
Low
Report
Candel Therapeutics Announces Proposed $100 Million Public Offering
2/19
04:01 pm
cadl
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
High
Report
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
2/11
08:53 am
cadl
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit [Yahoo! Finance]
Medium
Report
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit [Yahoo! Finance]
2/11
08:05 am
cadl
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
Medium
Report
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
2/4
06:00 pm
cadl
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight [Yahoo! Finance]
Medium
Report
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight [Yahoo! Finance]
2/2
04:21 pm
cadl
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/2
04:05 pm
cadl
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/14
07:11 pm
cadl
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Medium
Report
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term [Yahoo! Finance]